IL1B and AIDS: Anakinra, a recombinant form of the IL-1 receptor antagonist (IL1-RA) (accessed on March 8, 2019), canakinumab, a human monoclonal antibody blocking the interaction between IL-1β and the IL-1 receptor (European Medicines Agency, 2019b), and rilonacept, a soluble receptor predominantly blocking IL-1β (Tarp, et al., 2016; Junge et al., 2017), are the most prevalent anti-IL-1 therapies in polygenic AIDs.